FDA Issues Guidance on Postapproval Pregnancy Safety Studies
The FDA has released guidance to enhance the collection of safety data for drugs and biologics used during pregnancy.
Published: June 1, 2026
Updated: June 1, 2026
Author: Humanexa Intelligence
Therapeutic area: General / Drug Safety
Asset: General
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
General
Indication
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
Companies will need to adapt their postapproval studies to comply with new FDA recommendations, which may impact resource allocation and study designs.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor how companies adjust their safety study protocols and any resulting changes in drug labeling or approval processes.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.